Asia Pacific HIV Diagnostics Market to Surpass US$ 1,333.4 Mn by 2030

Asia Pacific HIV Diagnostics Market, by Product Type (Instruments and Reagents & Kits), by Test Type (Screening {Third Generation and Fourth Generation}, Differentiation & Confirmation Test, and Monitoring Test {CD4 Tests and Viral Load Tests}), by End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, and Others), and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific) is estimated to be valued at US$ 522.5 Million in 2022 and is expected to exhibit a CAGR of 12.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Various healthcare regulatory bodies are focusing on HIV/AIDS, owing to its high epidemic burden. Several policies and strategic programs are undertaken to reduce HIV burden by offering comprehensive care, diagnosis, and treatment services. Increasing government initiatives to eliminate HIV infections aid pregnant women and infants to get screened for HIV. This is expected to boost demand for HIV diagnostics instruments during the forecast period. For instance, in April 2017, Ministry of Health and Family Welfare, Government of India, launched ‘Test and Treat Policy for HIV’ policy, which is expected to improve longevity and quality of life of those infected with HIV. Similarly, in 2017, Ministry of Health, Sri Lanka initiated the National HIV/STI Strategic Plan (NSP) Sri Lanka 2018 – 2022. This strategic plan includes five objectives, which will supports NSP’s vision to make ‘Country free of new HIV infections, discrimination, and AIDS related deaths’.

Asia Pacific HIV Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a negative impact on the Asia Pacific HIV diagnostics market, owing to decrease in research and development activities to diagnose and treat HIV. For instance, according to the data published by the National Center for Biotechnology Information, since the beginning of the COVID-19 pandemic, many have been concerned that people with HIV (PWH) might encounter a more severe course of COVID-19 than the people without HIV due to the impaired inflammatory cell responses in PWH, leading to more complications and death. In PWH, barriers such as mental illness, drug abuse, homelessness, and alcohol consumption have increased the risk of COVID-19 infection and negatively impacted access to healthcare. The COVID-19 pandemic could have major adverse effects on the provision of health services for other major infectious diseases in low-income and middle-income countries. The researchers and clinicians were focused on developing the vaccines for the prevention of coronavirus. The COVID-19 pandemic kept the pathology laboratories engaged in the diagnosis and testing of the patients infected with coronavirus. The second pandemic wave in May 2021 was associated with a larger drop in utilization among MSM than PWID. Declines in both waves were statistically significant for MSM and PWID.

Asia Pacific HIV Diagnostics Market: Key Developments

In July 2022, India's government has took initiative to bring up its own testing kit for HIV. Three companies -- Ahmedabad-based Cadila Pharmaceuticals, Delhi-based firms ACE Diagnostics and J Mitra & Co are launched in July indigenously developed HIV diagnostics kits in the domestic market. The companies have scaled-up the technologies they had bought from public sector research institutes and have sought the approval of the Drug Controller General of India (DCGI) to commence commercial production. The kits - a peptide-based kit for Elisa test (from ACE), an immuno-western blot (J Mitra) and a recombinant chimeric reagent (Cadila Pharma) - would bring down the cost of HIV tests in the country by more than 200 per cent, sources said. The government being the major buyer of HIV kits through the National AIDS Control Organization (NACO), the companies have already approached the Union health ministry for signing a purchase agreement. The ministry is understood to be of the view that National Aids Control Organization, a division of the Ministry of Health and Family Welfare, Government of India could restrict the buying to Indian firms once the technologies are validated.

In July 2022, according to the global health agency, the World Health Organization (WHO) released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV and called for countries to consider this safe and highly effective prevention option for people at substantial risk of HIV infection. According to the global health agency, CAB-LA is an intramuscular injectable, long-acting form of PrEP, with the first 2 injections administered 4 weeks apart, and followed by cabotegravir injection every 8 weeks.

Browse 22 Market Data Tables and 14 Figures spread through 178 Pages and in-depth TOC on “Asia Pacific HIV Diagnostics Market”-  Forecast to 2030, Asia Pacific HIV Diagnostics Market, by Product Type (Instruments and Reagents & Kits), by Test Type (Screening {Third Generation and Fourth Generation}, Differentiation & Confirmation Test, and Monitoring Test {CD4 Tests and Viral Load Tests}), by End User (Hospitals and Clinics, Diagnostic Laboratories, Home Care Settings, and Others), and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific)

o know the latest trends and insights related to Asia Pacific HIV Diagnostics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/asia-pacific-hiv-diagnostics-market-2457

Moreover, increasing government initiatives for bringing up diagnosis of HIV is expected to drive the market over the forecast period. For instance, in February 2022, government of India allowed 5% import duty on diagnostics kits for the detection of Hepatitis B and HIV to boost domestic manufacturing based on the recommendations of the Association of Diagnostics Manufacturers of India (ADMI). Association of Diagnostics Manufacturers of India (ADMI) had made recommendations to the Union Ministry of Finance in November 2021 regarding custom duties on in- vitro diagnostics (IVD) items falling under Lists 3 and 4 of the Customs Tariff list. Items falling under List 3 attract concessional duty of 5% while those falling under List 4 are exempted from import duty.  List 4 includes critical items such as lifesaving drugs and diagnostics tests amongst others.

Key Takeaways of the Asia Pacific HIV Diagnostics Market:

• The Asia pacific HIV diagnostics market is expected to exhibit a CAGR of 12.4% during the forecast period due to the increasing demand for home testing HIV diagnosis is encouraging the key players in the market to focus on developing portable, easy-to-use, and rapid diagnosis test. For instance, in November 2018, Atomo Diagnostics’ Atomo HIV Self-Test was approved for sale in Australia by the Therapeutic Goods Administration (TGA). It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator. There are various low-cost commercial tests used in low-resource settings for HIV screening. Moreover, most of the ready-to-use types of rapid flow tests are adopted by emerging economies, owing to cheap cost, convenient, portable, and requirement of few or no reagents or equipment, and ability to provide results within 30 minutes. Most of the HIV infection diagnosis kits are deigned to work with a company’s own HIV analyzer, which offers exclusivity to deliver standardized testing results. For instance, F. Hoffmann-La Roche AG’s Food and Drug Administration approved COBAS AmpliPrep/COBAS TaqMan HIV-1 Test is an in-vitro nucleic acid amplification test for the quantitation of Human Immunodeficiency Virus (HIV-1) nucleic acid in human plasma. It is designed to use with the COBAS AmpliPrep Instrument and the COBAS TaqMan Analyzer or COBAS TaqMan 48 Analyzer for automated amplification and detection.
• Among Countries, India is estimated to account for the largest market share in the Asia pacific HIV diagnostics market over the forecast period, owing to the increasing prevalence of the HIV in the region. For instance, according to the Center for Disease Control and Prevention, the number of people contracting HIV (human immunodeficiency virus) in the last 10 years has come down significantly. HIV transmission by unprotected sex was recorded in 2.4 lakh people in 2011-12, while the number reduced to 85,268 in 2020-21. Among the states, Andhra Pradesh recorded the highest number of such cases of HIV transmission at 3,18,814 followed by Maharashtra at 2,84,577, Karnataka at 2,12,982, Tamil Nadu at 1,16,536, Uttar Pradesh at 1,10,911 and Gujarat at 87,440 cases in 2021. As of 2020, there are 23, 18,737 people living with HIV, including 81,430 children, in India.
• Major players operating in the Asia pacific HIV diagnostics market include Abbott Laboratories, Merck KGaA, F. Hoffmann-La Roche AG, Atomo Diagnostics, Siemens Healthineers, Inc., bioLytical Laboratories Inc., MedMira Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., and Danaher Corporation